New radioactive therapy targets Hard-to-Treat thyroid cancer
NCT ID NCT02088645
First seen May 04, 2026 · Last updated May 20, 2026 · Updated 2 times
Summary
This early-phase study tests a radioactive drug called 177Lu-PP-F11N in people with advanced medullary thyroid cancer that has spread. The drug is designed to seek out and attach to cancer cells, allowing doctors to see them on scans and deliver radiation therapy. The study aims to find the safest dose and see how well it works, with 24 participants expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR GEP GRADE 1-3 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Basel, Clinic for radiology and nuclear medicine
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.